{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:47:43Z","timestamp":1788306463112,"version":"build-2803163510"},"reference-count":35,"publisher":"SLACK, Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pediatr Ophthalmol Strabismus"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:p>\n            Topical glaucoma medications are widely used for childhood glaucoma, although little is known concerning the use of the newer glaucoma medications in this population. The majority of the references cited were extracted from PubMed. A literature review of all English language reports related to glaucoma medication in the pediatric population since 1980 was performed. Medical therapy of pediatric glaucoma contains four groups of drugs: \u03b2-blockers (timolol and betaxolol), carbonic anhydrase inhibitors (dorzolamide), \u03b12-agonists (brimonidine), and prostaglandin analogs (latanoprost). Timolol is the first choice in pediatric glaucoma. In cases with insufficient reduction of the intraocular pressure (IOP), the combination of timolol once a day and dorzolamide twice a day brings about a good control of the IOP. Both medications are effective and well tolerated. The \u03b12-agonists have more and potentially serious adverse effects in children and are contraindicated for children younger than 2 years of age. Latanoprost tends to be less effective in lowering IOP in children than in adults. However, no studies are reported where latanoprost is used in monotherapy. Additional study may further delineate this drug's role in treating pediatric glaucoma. The safety profile of latanoprost in children appears excellent.\n            <jats:bold>[J Pediatr Ophthalmol Strabismus 2009;46:12\u201318.]<\/jats:bold>\n          <\/jats:p>","DOI":"10.3928\/01913913-20090101-05","type":"journal-article","created":{"date-parts":[[2009,3,16]],"date-time":"2009-03-16T18:28:29Z","timestamp":1237228109000},"page":"12-18","source":"Crossref","is-referenced-by-count":69,"title":["The Safety and Efficacy of Glaucoma Medication in the Pediatric Population"],"prefix":"10.3928","volume":"46","author":[{"given":"Greet","family":"Coppens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg","family":"Stalmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Zeyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingele","family":"Casteels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.icu.0000134878.48361.50"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1985.01050080075024"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/000992289803701101"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702850"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ohc.2005.05.006"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(84)34141-0"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(81)35043-X"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.9.1177"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2006.07.001"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1091-8531(98)90109-4"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-199502000-00012"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200709020-00001"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-8994(96)00228-7"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3180a72154"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.8.1052"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0181-5512(07)89657-4"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpa.2001.117571"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.06.035"},{"key":"e_1_3_1_20_2","first-page":"155","article-title":"Ocular hypertension in children treated with brimonidine 0.2%: a clinical study [article in Spanish]","volume":"81","author":"Montero-de-Espinosa I","year":"2006","unstructured":"Montero-de-Espinosa I, M\u00e1rquez-de-Aracena R, Morales C. Ocular hypertension in children treated with brimonidine 0.2%: a clinical study [article in Spanish]. Arch Soc Esp Oftalmol. 2006;81:155\u2013159.","journal-title":"Arch Soc Esp Oftalmol"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/000992280404300114"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2006.00734.x"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6700520"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.111319"},{"key":"e_1_3_1_25_2","first-page":"763","article-title":"Treatment of glaucoma with brimonidine (Alphagan 0.2%) [article in French]","volume":"23","author":"Detry-Morel M","year":"2000","unstructured":"Detry-Morel M, Dutrieux C. Treatment of glaucoma with brimonidine (Alphagan 0.2%) [article in French]. J Fr Ophtalmol. 2000;23:763\u2013769.","journal-title":"J Fr Ophtalmol"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(02)00303-X"},{"key":"e_1_3_1_27_2","first-page":"243","article-title":"The effectiveness of latanoprost for the treatment of pediatric glaucoma","volume":"106","author":"Urban B","year":"2004","unstructured":"Urban B, Bakunowicz Lazarczyk A, Mrugacz M, Ozieblo Kupczyk M. The effectiveness of latanoprost for the treatment of pediatric glaucoma. Klin Oczna. 2004;106:243\u2013244.","journal-title":"Klin Oczna"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1091-8531(99)70092-3"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.9.1091"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00129-9"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-199906000-00009"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(97)80008-2"},{"key":"e_1_3_1_33_2","first-page":"2007","volume-title":"Basic and Clinical Science Course, Section 10: Glaucoma","author":"Simmons ST","unstructured":"Simmons ST, Cioffi GA, Gross RL, . Basic and Clinical Science Course, Section 10: Glaucoma. San Francisco: American Academy of Ophthalmology; 2007\u20132008."},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(78)35667-0"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2006.00733.x"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/112067210601600209"}],"container-title":["Journal of Pediatric Ophthalmology &amp; Strabismus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.healio.com\/doiresolver?doi=10.3928\/01913913-20090101-05","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T16:47:25Z","timestamp":1710780445000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/01913913-20090101-05"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.3928\/01913913-20090101-05"],"URL":"https:\/\/doi.org\/10.3928\/01913913-20090101-05","relation":{},"ISSN":["0191-3913","1938-2405"],"issn-type":[{"value":"0191-3913","type":"print"},{"value":"1938-2405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}